Clinical-stage biopharmaceutical company developing therapies for liver and metabolic diseases.
NGM Biopharmaceuticals, Inc. is a dynamic biopharmaceutical company dedicated to pioneering the discovery and development of innovative therapies targeting liver and metabolic diseases, retinal disorders, and cancer. Central to its portfolio are cutting-edge product candidates such as Aldafermin, an engineered analog of fibroblast growth factor 19 currently advancing through Phase IIb clinical trials for non-alcoholic steatohepatitis (NASH). Additionally, MK-3655, an agonistic antibody activating fibroblast growth factor receptor 1c-beta-klotho, is undergoing Phase IIb trials for type 2 diabetes and NASH treatment.
Further enhancing its robust pipeline, NGM Biopharmaceuticals is progressing NGM120, an antagonist antibody targeting GFRAL, through Phase I/II trials. This candidate holds promise for treating conditions like geographic atrophy. Meanwhile, NGM621, an immunoglobulin 1 monoclonal antibody, is also in Phase II trials for geographic atrophy treatment. The company's commitment extends to cancer therapies with NGM707, a dual antagonist monoclonal antibody in Phase I/II trials aimed at advanced solid tumors, along with NGM831 and NGM438 targeting the same indications.
NGM Biopharmaceuticals leverages strategic collaborations and licensing agreements to drive innovation. Notable partnerships include agreements with Merck Sharp & Dohme Corp. and Merck & Co., Inc., focusing on novel treatments for retinal and cardiovascular-metabolic diseases, including heart failure. These alliances underscore NGM's dedication to addressing unmet medical needs through groundbreaking scientific advancements.
Founded in 2007 and headquartered in South San Francisco, California, NGM Biopharmaceuticals continues to expand its influence in the biopharmaceutical sector, driven by a commitment to pioneering therapies that offer hope to patients facing challenging diseases worldwide.